NCT06785415 - Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

April 1, 2031

Study Completion Date

April 1, 2031

Conditions

Recurrent Multiple Myeloma

Interventions

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Chest Radiography

Undergo chest x-ray

PROCEDURE

Computed Tomography

Undergo CT and/or PET/CT

BIOLOGICAL

Daratumumab

Given SC

DRUG

Dexamethasone

Given PO

BIOLOGICAL

Elotuzumab

Given IV

DRUG

Iberdomide

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester